DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Neurocrine Biosciences, Inc. (NBIX)
« Back to company indexNBIX Chatter Timeline
Stock Ticker for NBIX
Most Active Tweeters for NBIX
No tweets foundRecent Tweets for NBIX
 |
@humour411 @CNBCClosingBell For every $nbix for ex, there are 20 others that will make you stay away from biotech for the rest of of your entire life ? August 22nd 2018, 1:08am |
 |
@beyond_ninety As Neurocrine Biosciences $NBIX Stock Rose, Holder Bb Biotech Ag Decreased Its Stake; As Toronto Dominion Bank $TD… https://t.co/mSfMRiXhaE August 21st 2018, 2:08pm |
|
@beyond_ninety Neurocrine Biosciences $NBIX Holder Columbus Circle Investors Raised Holding; Davis Selected Advisers Has Increased… https://t.co/WlQ7vDqr2v August 21st 2018, 1:08pm |
|
@beyond_ninety Rhenman & Partners Asset Management Ab Trimmed Neurocrine Biosciences $NBIX Stake by $653,458; As General Mtrs Co… https://t.co/WHNxmMlO92 August 21st 2018, 9:08am |
 |
@MareaInformativ Somewhat Positive Media Coverage Somewhat Unlikely to Affect Neurocrine Biosciences $NBIX Stock Price https://t.co/qDoUUGYhU9 August 20th 2018, 9:08pm |
 |
@usindexlive Proshare Advisors Lowered Neurocrine Biosciences $NBIX Holding; Bridge Bancorp $BDGE Has 1.37 Sentiment https://t.co/ZCgDgAzUvv August 20th 2018, 2:08pm |
 |
@WeekHerald Brokerages Expect Neurocrine Biosciences, Inc. $NBIX Will Announce Earnings of $0.43 Per Share https://t.co/L0ChsnQtvO August 20th 2018, 2:08pm |
 |
@OlympiaReport Zacks: Brokerages Expect Neurocrine Biosciences, Inc. $NBIX to Post $0.43 EPS https://t.co/2tcUVvKs14 August 20th 2018, 2:08pm |
 |
@ThisLincolnian Neurocrine Biosciences, Inc. $NBIX Expected to Post Quarterly Sales of $150.70 Million https://t.co/YcCqT3oYr5 August 20th 2018, 1:08pm |
 |
@registrarjourn First Mercantile Trust Co. Purchases 1,334 Shares of Neurocrine Biosciences, Inc. $NBIX https://t.co/3mshGolMUo August 20th 2018, 2:08am |
 |
@EnterpriseLeade First Mercantile Trust Co. Purchases 1,334 Shares of Neurocrine Biosciences, Inc. $NBIX https://t.co/XVnygGpQsG August 20th 2018, 2:08am |
 |
@mdy @jlowin $NBIX (I use a US-based shipping service so in the unlikely event that I win, you won't have to figure out international shipping.) August 18th 2018, 11:08am |
 |
@ConsumerFeed $0.43 Earnings Per Share Expected for Neurocrine Biosciences, Inc. $NBIX This Quarter https://t.co/4U6BNQXM1e August 18th 2018, 9:08am |
 |
@MarketChmln $NBIX upcoming event August 19: Opicapone at the 2018 World Congress on Parkinson https://t.co/9qUJYfFOkO August 18th 2018, 8:08am |
|
@registrarjourn Neurocrine Biosciences, Inc. $NBIX Given Consensus Recommendation of “Buy” by Brokerages https://t.co/LdJvOdKGGH August 18th 2018, 3:08am |
|
@EnterpriseLeade Neurocrine Biosciences, Inc. $NBIX Given Consensus Recommendation of “Buy” by Brokerages https://t.co/tfyHjDp6xm August 18th 2018, 3:08am |
 |
@esimian @pawcio2009 $NBIX...am I the first one? No brainer in my mind...$SRPT #2 August 17th 2018, 6:08pm |
|
@registrarjourn Analyzing Fennec Pharmaceuticals $FENC & Neurocrine Biosciences $NBIX https://t.co/wBbR6LVLiA August 17th 2018, 6:08pm |
|
@EnterpriseLeade Analyzing Fennec Pharmaceuticals $FENC & Neurocrine Biosciences $NBIX https://t.co/9WLVKpXAwe August 17th 2018, 6:08pm |
|
@registrarjourn $150.70 Million in Sales Expected for Neurocrine Biosciences, Inc. $NBIX This Quarter https://t.co/5OYYcvQbW0 August 17th 2018, 6:08am |
|
@EnterpriseLeade $150.70 Million in Sales Expected for Neurocrine Biosciences, Inc. $NBIX This Quarter https://t.co/xgW9CsDYWj August 17th 2018, 6:08am |
 |
@AmericanBanking $150.70 Million in Sales Expected for Neurocrine Biosciences, Inc. $NBIX This Quarter https://t.co/pxCqZiahcs #stocks August 17th 2018, 4:08am |
|
@registrarjourn Neurocrine Biosciences $NBIX Given a $128.00 Price Target at Oppenheimer https://t.co/Sb1EXKxEl2 August 17th 2018, 12:08am |
|
@EnterpriseLeade Neurocrine Biosciences $NBIX Given a $128.00 Price Target at Oppenheimer https://t.co/4tv8Ey74xW August 17th 2018, 12:08am |
|
@AmericanBanking Neurocrine Biosciences $NBIX – Research Analysts’ Recent Ratings Updates https://t.co/SYTGbtQtbE #stocks August 16th 2018, 8:08pm |
|
@ThisLincolnian Neurocrine Biosciences $NBIX – Research Analysts’ Recent Ratings Updates https://t.co/PEUPTqvrQY August 16th 2018, 8:08pm |
|
@WeekHerald Neurocrine Biosciences $NBIX – Research Analysts’ Recent Ratings Updates https://t.co/z596Bsw7Et August 16th 2018, 8:08pm |
|
@usindexlive Baker Bros Advisors LP Has Cut Its Neurocrine Biosciences $NBIX Holding; 6 Analysts Bullish American Homes 4 Rent… https://t.co/dbsJxYBQxU August 16th 2018, 3:08pm |
 |
@The_CasualSmart Wms Partners Has Cut 3M Co $MMM Holding; Neurocrine Biosciences $NBIX Shorts Lowered By 1.23% https://t.co/aQeaqLTLqc August 16th 2018, 12:08pm |
 |
@Hypocrites_Oath RT @OpenOutcrier: $NBIX (+0.0% pre) Neurocrine Biosciences (NBIX) to Present Data on INGREZZA at IAPRD - SI https://t.co/7RgCCZZZq9 August 16th 2018, 8:08am |
 |
@OpenOutcrier $NBIX (+0.0% pre) Neurocrine Biosciences (NBIX) to Present Data on INGREZZA at IAPRD - SI https://t.co/7RgCCZZZq9 August 16th 2018, 8:08am |
|
@MareaInformativ Financial Review: Neurocrine Biosciences $NBIX and Curis $CRIS https://t.co/IiPogBVnpS August 16th 2018, 6:08am |
|
@registrarjourn Neurocrine Biosciences $NBIX Announces Earnings Results https://t.co/uzNR3jOhxG August 16th 2018, 5:08am |
|
@EnterpriseLeade Neurocrine Biosciences $NBIX Announces Earnings Results https://t.co/SXFeSoj2Rb August 16th 2018, 5:08am |
 |
@Russe9 RT @odibro: $NBIX to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Di… August 15th 2018, 11:08pm |
 |
@jacquilrr $NBIX-playing with my flag here a bit of a upside down cup here so still like it higher in time I am neutral to short here. August 15th 2018, 10:08pm |
 |
@Briefingcom $NBIX: Neurocrine Biosci will present data from its movement disorders programs, including additional long-term... https://t.co/8H6jbqLA49 August 15th 2018, 6:08pm |
 |
@hotpennyalerts $NBIX to reveal findings from its movement disorders programs https://t.co/bjXxl1DyPX August 15th 2018, 4:08pm |
 |
@stocknewsdotcom $NBIX Company will present data from its movement disorders programs, including additional long-term results for I… https://t.co/t0IL7TUD8F August 15th 2018, 4:08pm |
 |
@Allstocknews $NBIX Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congr From our Stock News Alerts App August 15th 2018, 4:08pm |
 |
@odibro $NBIX to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease an… https://t.co/4lTqG3AfXJ August 15th 2018, 4:08pm |
 |
@bthefirsttoknow $NBIX Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on… https://t.co/szrJaqaRMZ August 15th 2018, 4:08pm |
|
@MareaInformativ Neurocrine Biosciences $NBIX Issues Earnings Results https://t.co/8Hs1G3DS1T August 15th 2018, 3:08pm |
|
@AmericanBanking $0.43 EPS Expected for Neurocrine Biosciences, Inc. $NBIX This Quarter https://t.co/fcSe0bm3xa #stocks August 15th 2018, 3:08pm |
|
@MareaInformativ Neurocrine Biosciences $NBIX Coverage Initiated by Analysts at Stifel Nicolaus https://t.co/FSixQtBaOO August 15th 2018, 12:08pm |
 |
@BioWino $nbix blowout q... another blockbuster launching soon. right back to where it pre earnings blowout. August 15th 2018, 11:08am |
|
@usindexlive T $TMUS Holder Brighton Jones Upped Stake; Neurocrine Biosciences $NBIX Shareholder Cormorant Asset Management Has… https://t.co/WmOPekxILh August 15th 2018, 8:08am |
 |
@reurope_stock Were Analysts Bullish Neurocrine Biosciences, Inc. $NBIX This Week? https://t.co/OIuM1aoMlL August 15th 2018, 7:08am |
 |
@west_moreland Analysts take a look at Neurocrine Biosciences, Inc. $NBIX having this to say. https://t.co/cmT5HHiNgp August 15th 2018, 7:08am |
 |
@Fanob_stock Are Analysts Bearish Neurocrine Biosciences, Inc. $NBIX After Last Week? https://t.co/DKjK3y5CfM August 15th 2018, 7:08am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2018. All rights reserved.